Objective: The purpose of this observation was to evaluate the safety and efficacy of hydrocortisone (HC) for the treatment of refractory hypotension in term and preterm infants. A secondary purpose was to determine the utility of serum cortisol concentrations in predicting the response to treatment.
Introduction
Hypotension in the neonatal period can result in significant morbidity and mortality. In preterm infants it is associated with the development of intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL) and poor neurodevelopmental outcomes. [1] [2] [3] [4] Inadequate perfusion as a complication of sepsis, respiratory failure, severe birth depression or persistent pulmonary hypertension, is also detrimental to the critically ill term infant. While the etiologies of hypotension are multifactorial, there may exist a subset of infants with adrenal insufficiency manifesting as hypotension refractory to standard therapy. 5, 6 By analogy to the concentrations used in adults and children, 7 adrenal insufficiency in newborns has been defined as a baseline serum cortisol concentration p5 mg per 100 ml. 6, [8] [9] [10] However, not all infants with 'low' cortisol values appear to be compromised, and conversely infants with concentrations in the normal range can have a clinical picture consistent with cardiovascular compromise secondary to adrenal insufficiency. This latter condition has been described as 'relative adrenal insufficiency' with cortisol concentrations that may be appropriate for normal functioning, yet are inadequate in the setting of acute illness or prematurity. 11, 12 While the standard therapy for hypotension has included volume expansion with colloid or crystalloid and the administration of inotropic agents, glucocorticoids have been used successfully in patients with cardiovascular compromise related to adrenal dysfunction. 5, 6, 11, [13] [14] [15] [16] Because of concerns over short-and longterm side effects with dexamethasone, [17] [18] [19] hydrocortisone (HC) has been used as an alternative glucocorticoid. 20 However, HC treatment has been recently associated with spontaneous intestinal perforation (SIP). [21] [22] [23] We hypothesized that HC is effective in the treatment of refractory hypotension with an improvement of systemic arterial pressure, and that the degree of response would depend on pretreatment baseline cortisol concentrations.
Methods
The purpose of this retrospective review was to evaluate the shortterm outcomes of a cohort of infants treated according to a protocol for refractory hypotension developed for the Holden neonatal intensive care unit (NICU) of the University of Michigan Health System from 2001 to 2004. Patients so treated during this period were identified using an institutional pharmacy database. Patients were considered refractory to treatment if there was hypotension with signs of inadequate perfusion despite management with volume expansion and a combined inotrope total (dopamine and dobutamine) dose >20 mg per kg per min.
In this protocol hypotension was defined pragmatically as a mean arterial pressure (MAP) (mm Hg) value < gestational age (GA) (weeks). 24 It is recognized that MAP is used as a surrogate measure of cardiac output and as such is an imperfect tool. Other measurements/tools may be more accurate but these modalities are not yet clinically available nor is their use widespread. Similarly, there is widespread variation in the definition of hypotension and measurement of arterial pressure in newborn infants. 25 With acknowledgement of the above limitations, the commonly accepted definition of hypotension (MAP <GA) was used as it is frequently used clinically and it lends itself well as a working bedside tool.
Similarly, it is recognized that dopamine and dobutamine have different distinct pharmacologic properties and a combined total dose may not be technically pharmacologically equivalent. However, it was felt that a combined total dose does represent a reasonable and simple surrogate for severity of illness, hence its use in the protocol.
Signs of decreased perfusion included either a decrease in urine output (<1 ml kg À1 h À1 ) for 2 h or a capillary refill time >3 s. Patients were excluded if they had received prior glucocorticoid treatment, if they had major congenital or chromosomal anomalies or if data were incomplete due to patients expiring during the first 12 h of treatment.
The primary outcomes of interest were the change in MAP and the change in the dose of inotrope after the initiation of HC treatment. Secondary outcomes included the relationship between baseline serum cortisol concentrations and GA or birth weight, the magnitude of response in arterial pressure and inotrope dose change after treatment with HC and resolution of oliguria (urine output <1.0 ml kg À1 h
À1
). Data collected included GA, birth weight, postnatal age at the time of HC administration, pretreatment baseline serum cortisol concentration, concomitant medications, urine output, MAP and the total inotrope dose at baseline, and at 2, 6, 12 and 24 h after the initial HC administration. Adverse events included fungal and bacterial infections, new or worsening IVH, PVL, hyperglycemia requiring insulin and gastrointestinal perforation. Where possible the etiology of gastrointestinal perforation was determined based on surgical observation, and/or pathological examination. Baseline cortisol concentrations were determined by an ADVIA Centaur Cortisol Assay, a competitive immunoassay using direct chemiluminescence. MAP was measured using an indwelling arterial catheter when available, or by a noninvasive automated oscillometric cuff. All other documentation was collected from the bedside nursing record, electronic medical record and bedside medical chart. The project was approved by the Institutional Review Board of the University Of Michigan Medical School. Because this observation was a retrospective review of existing data, informed consent was waived.
Hydrocortisone protocol
In 2001, to improve the consistency of treatment of hypotension unresponsive to inotropes (refractory hypotension), a consensus panel comprised of physicians from Neonatal/Perinatal Medicine, Pediatric Endocrinology and Pediatric Pharmacists at the University of Michigan developed an HC dosing protocol for infants with refractory hypotension with an intent to provide standardized treatment to this population. The protocol was based on available adult and pediatric data for HC dosing as well as expert opinion. Baseline serum cortisol concentrations were measured prior to the administration of the first stress dose of HC. The baseline cortisol concentration was used to determine the extent of adrenal dysfunction, and to guide the maintenance dose regimen after the stress dose treatment for the first 48 h. A cortisol concentration <5 mg per 100 ml at baseline or at the scheduled check time during administration of HC according to the protocol was considered absolute adrenal insufficiency. The stress HC dose was defined as 45 mg m À2 per day (3 Â the dose accepted as physiologic in general practice). This dose was divided every 6 h. The stress HC dose was administered for the first 48 h of treatment of refractory hypotension regardless of the baseline cortisol concentration. The maintenance dose of HC was 15 mg m À2 per day (generally accepted replacement dose) divided every 6 h. After completion of the first 48 h of treatment with the stress dose, infants were placed on maintenance regimens or HC was discontinued; the decision was based on the baseline serum cortisol concentration. The infants in the 5 to 15 mg per 100 ml baseline cortisol group were reevaluated at 12 h after the completion of the stress regimen to determine the need for maintenance dosing. The serum cortisol concentration was measured 12 h after the last stress dose. If the concentration was <5 mg per 100 ml and/or the infant was hemodynamically unstable, the maintenance regimen was started. Otherwise, the HC was discontinued. The HC treatment for all infants who received the maintenance-dosing regimen was evaluated once a week to determine continued need. For these infants, two doses of HC were withheld on a Sunday evening and a cortisol concentration was measured on a Monday morning. If the cortisol concentration was X5 mg per 100 ml then the weaning schedule was instituted provided the infant was hemodynamically stable. This process was repeated every week until the infant could be placed on the weaning regimen (cortisol concentration X5 mg per 100 ml on a Monday morning measurement). The weaning schedule consisted of 50% of the maintenance HC dose (divided every 6 h) for 24 h followed by 25% of the maintenance dose for 24 h. It was necessary to withhold the two doses prior to determining the Monday morning cortisol concentration to avoid cross reactivity of exogenous HC with endogenous cortisol in the assay.
Statistical analysis
Baseline cortisol concentrations, birth weights and GAs were compared between patients surviving p12 h and those surviving >12 h, by two-tailed t-test. One sample t-tests were performed to evaluate the percent increase in MAP and the percent reduction in inotrope doses from baseline at 2, 6, 12 and 24 h after the administration of HC. Repeated measures analysis of variance (ANOVA) with Newman-Keuls post hoc testing was performed to compare differences in the increase in arterial pressure and reduction of total inotrope dose among the four time points. A w 2 test was performed to determine if the reduction in the proportion of patients with oliguria from before HC treatment to after institution of HC therapy was significant.
To evaluate the relevance of the baseline cortisol concentrations, a simple regression was performed to determine the relationship between baseline cortisol concentrations and GA or birth weight. Simple regressions were also performed to determine if there was a relationship between baseline cortisol concentrations and percent changes in arterial pressure and inotrope doses at each of the time points. To determine if there were subsets of infants who responded differently based on apparent degree of adrenal insufficiency, patients were stratified based on pretreatment cortisol concentrations. A repeated measures ANOVA was performed using two separate approaches to stratification. One approach used the cutoff baseline cortisol concentrations in our dosing protocol to generate the strata (<5, 5 to 15 and >15 mg per 100 ml). A second approach was determined based on a previously unpublished preliminary analysis to generate four strata (p4, >4 to p7, >7 to p10 and >10 mg per 100 ml). w 2 -tests were performed to compare outcome data for different weight groups (ELBW (extremely low birth weight) p1000 g, VLBW (very low birth weight) 1001 to 1500 g, LBW 1501 to 2500 g and infants >2500 g) with regard to inotrope duration, duration of treatment, postnatal age at treatment, culture positive sepsis, hyperglycemia requiring insulin, IVH, PVL and intestinal perforation.
Results
A total of 188 patients were admitted to the NICU and treated with inotropes and HC between December 2001 and January 2004. Of these, 117 patients were included in the analysis. Of the 71 patients not included, 20 had incomplete or missing data, 17 patients had major chromosomal or congenital abnormalities, 21 patients received glucocorticoids from referring hospitals prior to transfer and 13 patients died within the first 12 h of treatment. These patients were included in the analysis of the relation between baseline cortisol concentrations and GA and birth weight only. While there was no statistically significant difference in baseline cortisol concentrations, those infants expiring in the first twelve hours had a significantly lower birth weights and GA than those surviving the first 12 h (Figure 1 ). Many of these 13 infants who were excluded from the final analysis received incomplete courses of HC prior to expiring and did not survive long enough to allow meaningful collection of data. For these 13 patients the median baseline cortisol concentration was 12.4 mg per 100 ml with an inter-quartile range (IQR) 3.3 to 38.9 mg per 100 ml. Baseline cortisol concentrations and demographics of the 117 patients included in the final analysis appear in Table 1 . There was no relationship between baseline cortisol concentrations and GA (R ¼ 0.088), or birth weight (R ¼ 0.028). Because our population appeared bimodal on visual inspection of GA and birth weight distributions (Figures 1b and c) , the relationships between cortisol concentrations and GA or birth weight were reevaluated for ELBW infants and X2500 g birth weight infants. In these two subgroups there was also no relationship between cortisol concentrations and GA or birth weight.
There was a significant percent increase in MAP above the pretreatment baseline at each of the time points 2, 6, 12 and 24 h after treatment (P<0.0001, one-sample t-test vs null hypothesis of no change) (Figure 2 ). Evaluating differences amongst the four time points by ANOVA with post hoc testing, the only significant difference seen was between the percent increase at 2 h compared to those at 6, 12 and 24 h (P<0.001 at each time point). Differences among the time points 6, 12 and 24 h were not statistically significant (P>0.05 for each comparison). This suggests that after the administration of HC there was a significant improvement in MAP at 2 h after treatment that continued to improve until 6 h and was then maintained. Regarding the percent reduction in total inotrope dose, there was not a significant reduction at 2 h (P ¼ 0.22), but there was a significant reduction at 6 (P ¼ 0.017), 12 (P<0.0001) and 24 h (P<0.0001) compared to the baseline (pre-HC). Comparing the differences among time points, there was not a significant reduction in inotrope dose between the 2 and 6 h time points (P>0.05), but there was a significant reduction between 2 and 12 h, and between 2 and 24 h (both P<0.001). There was also a significant difference in inotrope dose between 6 and 12 h (P<0.01), between 6 and 24 h (P<0.001) and between 12 and 24 h (P<0.001). This indicates a significant and progressive reduction in inotrope dose from 6 to 24 h after the initiation of HC. HC treatment was also associated with a significant reduction in the number of patients with oliguria; 25.6% (95% CI: 18.0 to 34.5) of all infants were oliguric prior to HC treatment compared to 6.8% (95% CI: 3.0 to 13.0) with oliguria in the 16 h after initiation of treatment with HC (P<0.0002) ( Table 2) . To determine if there existed subsets of infants with differing responses based on pretreatment (baseline) cortisol concentrations, two different stratifications were used. Using the grouping based on the HC dosing protocol (<5, 5 to 15 and >15 mg per 100 ml), there was no significant difference in the reduction of inotrope dose (P ¼ 0.58) or the increase in MAP (P ¼ 0.67) among the different strata. An alternate stratification was used to further refine and investigate outcomes in infants with 'lower' cortisol concentrations. This grouping was based on cortisol concentrations of <4, 4 to 7, 7 to 10 and >10 mg per 100 ml. This also showed no difference among strata with regard to the reduction in pressor dose (P ¼ 0.28), or increase in MAP (P ¼ 0.68). When we limited analysis of treatment responses according to either of the above baseline cortisol stratification schemes, to either the p1000 g or the X2500 g subgroups, there was still no difference among strata with regard to increase in MAP or reduction in pressor dose.
Adverse outcomes after treatment with HC were also investigated ( Table 2. ). There were four cases of grade III to IV IVH (5.98%; 95% CI ¼ 2.4 to 11.9%) diagnosed after treatment. Three patients (2.56%; 95% CI ¼ 0.53 to 7.31%) were diagnosed with PVL after treatment. There were 21 patients (18.0%; 95% CI ¼ 11.5 to 26.1%) with positive blood cultures at any time after treatment with HC and 35 patients (29.9%; 95% CI ¼ 21.8 to 39.1) with insulinrequiring hyperglycemia. Among the 117 patients studied, the total number of gastrointestinal perforations was five (4.3%; 95% CI ¼ 1.4 to 9.7%). Of the five, two cases were clearly documented and related to necrotizing enterocolitis (NEC). The remaining three did not have enough documentation to make a distinction between NEC or SIP. Thus theses three infants represent the maximum possible incidence of SIP in the study population, and are represented in Table 2 as SIP. All perforations occurred in infants <1000 g.
There were other significant differences between the ELBW group of patients and other weight groups. These patients (ELBW) were more likely to start treatment with HC later (P<0.0001), and have longer durations of treatment (P<0.0001). They were also more likely to have treatment with inotropes discontinued within 24 h (P ¼ 0.006). They were also more likely to develop insulinrequiring hyperglycemia (P ¼ 0.0003) and to have culture positive sepsis (P<0.00001).
Discussion
Despite the widely held belief that the association between the administration of HC and an improvement in arterial pressure in critically ill infants has been well documented, there are few studies designed to investigate this. A careful review of the literature yielded seven studies specifically designed to look at the effect of HC administration on arterial pressure in infants. 5,6,11,13,26 -28 Six of these reported arterial pressure measurements per se. In these six a total number of 113 patients (including both term and preterm infants) are reported. Our observation with 117 patients represents a combined number of patients greater than the sum of these studies. Additionally, only two of the six studies mentioned are able to characterize the early (hours) response to HC. 5, 13 In the present study there was a documented improvement in arterial pressure by 2 h that was sustained at 6, 12 and 24 h after administration of HC (Figure 2) .
Although this study reports results in a heterogeneous population of infants, with a heterogeneous etiology for hypotension, the administration of HC was uniformly associated with an increase in arterial pressure, a decrease in the dose of inotropes and a reduction in oliguria. This improvement in clinical status was independent of GA, birth weight and pretreatment baseline cortisol concentrations. Hence, it appears acceptable to report findings from these infants as 'grouped'.
It is recognized that measurement of arterial pressure may be suboptimal as a surrogate outcome measure for cardiac output. Only one of the previously cited papers attempts to correlate the use of HC with another measure of cardiac output, urine output. 28 In that small series oliguria was not a problem prior to HC treatment, and urine output did not change after HC. 28 In contrast, we report that the use of HC is associated with an improvement in urine output.
Another goal of this study was to determine the utility of serum cortisol concentrations in the treatment of critically ill newborns. Particularly in VLBW infants, adrenal insufficiency is a common problem, 16, 29 and may be a contributor to inotrope resistance.
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Although commonly used the utility of baseline serum cortisol concentrations remains unclear. Because preterm infants do not secrete cortisol based on a circadian rhythm 30 and because newborns generally lack diurnal variation in cortisol, 31 random baseline cortisol concentrations have been regarded as an adequate marker of adrenal function. In adults, concentrations ranging from <5 mg per 100 ml 7 to 10 to 15 mg per 100 ml 32 have been considered insufficient during acute illness. In ELBW infants, a concentration of 5 mg per 100 ml has been more commonly used to represent adrenal insufficiency, 6, [8] [9] [10] and concentrations >15 mg per 100 ml have been used to represent adequate adrenal function. 10 However, previous reports document the notable variation in cortisol concentrations related to GA, birth weight, severity of illness and response to treatment. 6,8,9,13,16,22,29,33 -44 Considering this wide variation, our hope was to further clarify the usefulness of baseline cortisol concentrations to predict the degree of response to HC administration and help further identify infants with absolute and relative adrenal insufficiency based on pretreatment cortisol concentrations. The baseline serum cortisol concentrations of critically ill newborns in this study (median ¼ 6.3 mg per 100 ml, IQR ¼ 2.9 to 14.3 mg per 100 ml) ranged from low to normal using the commonly designated definitions. Cortisol concentrations did not correlate with GA or birth weight, and furthermore there was no correlation with response to HC treatment.
Other studies suggest that subsets of infants may behave differently with regard to cardiovascular compromise based on cortisol concentrations. 11, 44 We stratified infants in this study based on pretreatment cortisol concentrations to determine if there were cut points to predict response to treatment. However, post hoc analysis showed no significant differences. Again we recognize the heterogeneity in this study with respect to birth weight, and GA; however, neither of these two factors correlated with cortisol concentrations nor did patient response to treatment. Our findings do not support the use of baseline serum cortisol concentrations as a marker of critical illness or as a predictor of response to HC treatment.
Another goal of this study was to determine the safety of HC to treat refractory hypotension in critically ill newborns. Dexamethasone administration has been associated with an increased risk of intestinal perforations in ELBW infants, 18, 45 and there may also be an association between SIP and treatment with HC. In ELBW infants treated with HC, two recent studies describe SIP event rates of 9 23 and 16% 22 compared to 2 and 0%, respectively, in controls. In this observational study, five ELBW infants developed gastrointestinal perforation, of which three may have had SIP, for a presumptive SIP rate of 8.1% (95% CI 1.7 to 21.9) of our HC-treated ELBW infants. The presumptive SIP rate in HC-treated ELBW infants in the study period is similar to that of institutional historic controls (5.7%, 95% CI 1 to 16%), for 2000, the first year in which that diagnosis was tracked separately from NEC. The SIP rate in our HC-treated ELBWs is similar to that reported (7%) in non-corticosteroid-treated control ELBWs of two other studies. 18, 46 The range of reported SIP rates in control groups cited above (0 to 7%) must be interpreted with caution in comparison to our findings, because it is derived only from clinical trials of prophylactic corticosteroids to prevent bronchopulmonary dysplasia, not from hypotension treatment trials. Concerns about the risk of SIP associated with HC use must be weighed against the risks of morbidity and mortality associated with refractory hypotension.
There are also concerns regarding a potential association between concurrent indomethacin and HC administration and SIP, 22, 23 but this association remains unclear. In this study, two of the three patients who may have had SIPs were concurrently treated with indomethacin. Overall 32 patients received indomethacin at some point during their hospitalization, and 13 of these patients received indomethacin concurrently. Due to the small number of patients with intestinal perforations, and the lack of a clear etiology, interpretation of this association needs further investigation than these numbers provide. The concurrent use of indomethacin and HC is of concern, and should be approached cautiously.
Other potential adverse effects of glucocorticoid administration to newborns include adrenal suppression, hyperglycemia, IVH, PVL and an increased risk of infection. The rates of grade III to IV IVH and of PVL in ELBW infants in this study (5.5%, 95% CI 0.7 to 18.2 for grade III to IV IVH; 8.1%, 95% CI 1.7 to 21.9 for PVL) are similar to those of institutional historic controls (13%, 95%CI 8 to 20 for grade III to IV IVH and 2%, 95% CI 0 to 6 for PVL) over the 3-year period 1998 to 2000. The rates of nosocomial bacterial and fungal infections in ELBW infants in this study (32.4%, 95% CI 18 to 49.8 for bacterial; 10.8%, 95% CI 3 to 25.4 for fungal) are similar to those of institutional historic controls from 1998 to 2000 (24%, 95% CI 18 to 32 for bacterial; 10%, 95% CI 6 to 16 for fungal). Comparing the ELBW infants in this study to those receiving glucocorticoid treatment in other studies, the frequency was similar for hyperglycemia requiring insulin, 46 and nosocomial infections (bacterial and fungal), 18, 23, 46 but lower than reported for severe IVH. 18, 23, 46 This is one of the largest observations describing an improvement in arterial pressure with a standardized protocol for glucocorticoid administration to treat refractory hypotension in both preterm and term newborns. It is also one of the few that shows an improvement in an indirect measure of renal perfusion with a significant reduction in the number of patients with oliguria. One of the limitations of this observation is the retrospective design. This limits the description of and further clarification of intestinal perforation. It also limits the information that could be gained from infants who expired prior to the meaningful collection of data. Additional studies are needed to evaluate the utility of free cortisol concentrations in assessing adrenal insufficiency and the prediction of a therapeutic response. While this study also represents a heterogeneous population with respect to birth weight, GA and etiology of illness, it is important to note that independent of these factors HC administration was associated with a significant clinical improvement. Further investigation of the infants that did not respond to HC would potentially be clinically useful.
Conclusion
In neonates with refractory hypotension, HC administration is associated with a sustained increase in MAP, a decreased need for inotropic support and a reduction in the number of patients with oliguria. Baseline serum cortisol concentrations showed no correlation with GA, birth weight or severity of illness, and do not predict response to treatment with HC.
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